Classical Complement Inhibition By SAR445088 (BIVV020) in Adults with Cold Agglutinin Disease: Safety, Tolerability and Activity Results from the Open-Label, Non-Randomized, Single-Dose Phase 1b Study

被引：1

作者：

D'Sa, Shirley ^{[1
]}

Vos, Josephine M. I. ^{[2
,3
]}

Barcellini, Wilma ^{[4
]}

Wardecki, Marek ^{[5
]}

Perrin, Laurent ^{[6
]}

Barker, Graham ^{[7
]}

Zilberstein, Moshe ^{[8
]}

Storek, Michael ^{[9
]}

Chow, Timothy ^{[9
]}

Roeth, Alexander ^{[10
]}

机构：

[1] Univ Coll London Hosp NHS Fdn Trust, Ctr Waldenstroms Macroglobulinemia & Related Cond, London, England

[2] Univ Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

[3] Sanquin, Amsterdam, Netherlands

[4] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[5] Sanofi, Warsaw, Poland

[6] Sanofi, Montpellier, France

[7] Sanofi, Chilly Mazarin, France

[8] Sanofi, Bridgewater, NJ USA

[9] Sanofi, Cambridge, MA USA

[10] Univ Duisburg Essen, Univ Hosp Essen, Dept Hematol & Stem Cell Transplantat, Essen, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-177886

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 33 条

[1] Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial
Boinpally, Ramesh
Jakate, Abhijeet
Butler, Matthew
Borbridge, Lisa
Periclou, Antonia
[J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (07): : 726 - 733
[2] Single-Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial
Boinpally, Ramesh
Lu, Kaifeng
[J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (07): : 857 - 864
[3] PHARMACOKINETICS AND TOLERABILITY OF A SINGLE DOSE OF APRAGLUTIDE IN SUBJECTS WITH NORMAL AND IMPAIRED RENAL FUNCTION: A PHASE 1, OPEN-LABEL, NON-RANDOMIZED, PARALLELGROUP STUDY
Greig, Gerard
Hurley, Niamh
Michel, Eric
Youssef, Nader N.
[J]. GASTROENTEROLOGY, 2022, 162 (07) : S654 - S654
[4] The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg are Similar in Elderly and Nonelderly Adults: a Phase 1, Open-Label, Parallel-Group, Single-Dose Study
Croop, R.
Stringfellow, J.
Ivans, A.
Coric, V
[J]. HEADACHE, 2019, 59 : 177 - 178
[5] Rimegepant 75 mg Exposure, Safety, and Tolerability are Similar in Elderly and Nonelderly Adults: a Phase 1, Open-Label, Parallel-Group, Single-Dose Study
Ivans, Andrea
Stringfellow, Joseph
Coric, Vlad
Croop, Robert
[J]. NEUROLOGY, 2020, 94 (15)
[6] Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study
Sohn, Winnie
Winkle, Peter
Neutel, Joel
Wu, You
Jabari, Freeman
Terrio, Caitlin
Varrieur, Tracy
Wang, Jingying
Hellawell, Jennifer
[J]. CLINICAL THERAPEUTICS, 2022, 44 (09) : 1237 - 1247
[7] The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg Are Similar in Elderly and Nonelderly Adults: A Phase 1, Open-Label, Parallel-Group, Single-Dose Study
Bhardwaj, Rajinder
Morris, Beth
Bertz, Richard
Croop, Robert
Liu, Jing
[J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (01): : 37 - 44
[8] Rimegepant 75 mg Exposure, Safety, and Tolerability are Similar in Elderly and Nonelderly Adults: a Phase 1, Open-Label, Parallel-Group, Single-Dose Study
Croop, Robert
Stringfellow, Joseph
Ivans, Andrea
Coric, Vladimir
[J]. CEPHALALGIA, 2019, 39 : 30 - 30
[9] Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial
Li, Yingxin
Young Na, Joo
Zhu, Yunting
Oh, Jaeseong
Zhao, Amy
Jang, In-Jin
Tang, Lei
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024,
[10] A PHASE 1, OPEN-LABEL, SINGLE-DOSE, NON-RANDOMIZED STUDY TO EVALUATE PHARM ACOKIN ETICS AND PHARM ACO DYNAMICS OF EDOXABAN IN PEDIATRIC PATIENTS.
Zou, P.
Zahir, H.
Duggal, A.
Pandya, G.
Jin, J.
Leil, T.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S100 - S100

← 1 2 3 4 →